{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458773535
| IUPAC_name = (3Z)-N'-(1-hexyl-2-oxoindolin-3-ylidene)benzohydrazide
| image = MDA-19_structure.png
| width = 200

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 1048973-47-2 
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 25034599
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 24689676

<!--Chemical data-->
| C=21 | H=23 | N=3 | O=2 
| molecular_weight = 349.426 g/mol
| smiles = O=C(C1=CC=CC=C1)N/N=C(C2=CC=CC=C2N3CCCCCC)\C3=O
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C21H23N3O2/c1-2-3-4-10-15-24-18-14-9-8-13-17(18)19(21(24)26)22-23-20(25)16-11-6-5-7-12-16/h5-9,11-14H,2-4,10,15H2,1H3,(H,23,25)/b22-19-
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = ZGQHMZCITJHYOW-QOCHGBHMSA-N
}}

'''MDA-19''' is a drug that acts as a potent and selective [[agonist]] for the [[cannabinoid receptor]] [[Cannabinoid receptor 2|CB<sub>2</sub>]], with reasonable selectivity over the psychoactive CB<sub>1</sub> receptor, though with some variation between species. In animal studies it was effective for the treatment of [[neuropathic pain]], but failed to produce cannabis-like behavioural effects.<ref>{{Cite journal | last1 = Diaz | first1 = Philippe | last2 = Xu | first2 = Jijun | year = 2008 | title = Design and Synthesis of a Novel Series of N-Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2 Agonists for the Treatment of Neuropathic Pain | journal = J. Med. Chem. | volume = 51 | issue = 16 | pages = 4932–4947 | publisher = American Chemical Society | jstor =  | doi = 10.1021/jm8002203 | url =  | format =  | accessdate = | pmid=18666769}}</ref><ref>{{cite journal | last1 = Xu | first1 = JJ | display-authors = etal   | date = Jul 2010 | title = Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain | url = | journal = Anesthesia and Analgesia | volume = 111 | issue = 1| pages = 99–109 | pmid = 20522703 | doi=10.1213/ANE.0b013e3181e0cdaf | pmc=3253719}}</ref>

==See also==
* [[AM-1221]]
* [[JTE 7-31]]
* [[JWH-019]]
* [[JWH-133]]
* [[N-(S)-Fenchyl-1-(2-morpholinoethyl)-7-methoxyindole-3-carboxamide]]

==References==
{{reflist}}

{{Cannabinoids}}

[[Category:Cannabinoids]]


{{cannabinoid-stub}}